Full text is available at the source.
Abstract
Access to GLP-1 receptor agonists is strongly influenced by payer coverage and utilization management.
- Patient-level evidence regarding denial of GLP-1 receptor agonists across different payer types is limited.
- The coverage policies of payers can significantly affect the availability of GLP-1 receptor agonists for patients.
- Utilization management practices may restrict patient access to GLP-1 receptor agonists.
Simplified